Skip to main content

Advertisement

SpringerLink
Log in

Traditional and Novel Migraine Therapy in the Aging Population

  • Episodic Migraine (S Nahas, Section Editor)
  • Published:
Current Pain and Headache Reports Aims and scope Submit manuscript

Abstract

Migraine is a common disabling disorder that affects 36 million Americans. The clinical features of migraine are less typical in the people above age 60, making the diagnosis and treatment difficult in this group. In this review, we will discuss migraine-specific drugs and their use in populations about age 60 who suffer from migraine. This discussion will include an overview of traditional treatments for the acute and preventive treatment of migraine, and considerations for their use in patient populations above age 60. In addition, we will discuss newer agents that show a more promising safety profile.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

CGRP:

Calcitonin gene related peptide

NSAIDs:

Nonsteroidal anti-inflammatory drugs

TCA’s:

Tricyclic antidepressants

DHE:

Dihydroergotamine

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Hay S, Jayaraman S, Truelsen T, et al. A systematic analysis for the global burden of disease study. Lancet. 2015;(388):1545–602.

  2. Martins KM, Carlos A, Bordini C, et al. Migraine in the elderly: a comparison with migraine in young adults. Headache. 2016;(46):312–6.

    Article  Google Scholar 

  3. Mattson P, Svanrdsudd K, Lundberg PO, et al. The prevalence of migraine in women aged 40-74 years. A population based study. Cephalalgia. 2000;20:893–9.

    Article  Google Scholar 

  4. Waters WE. Epidemiological data relevant to prognosis in migraine in adults. Intern Med J Epidemiol 1975;(2):189–194.

  5. Hale WE, Perkins LL, May FE, et al. Symptom prevalence in the elderly. An evaluation of age, sex, disease and medication use. J Am Geriatr Soc. 1986;34:333–40.

    Article  CAS  Google Scholar 

  6. Fischer CM. Late life migraine accompaniments as a cause of unexplained transient ischemic attacks. Can J Neurol Sci. 1980;7:9–17.

    Google Scholar 

  7. Rappoprt AM, Sheftell FD, Baskin SM. Geriatric headaches. Geriatrics. 1983;(38):81–7.

  8. Raskin MN. The hypnic headache syndrome. Headache. 1988;28:534–6.

    Article  CAS  Google Scholar 

  9. Newland CA, Luis LS, Robinson PK et al. A survey of headache in the English city. Resident Clinic Study 1978;(5):1–20.

  10. Mazzota G, Gallai V, Alberti A, et al. Characteristics of migraine in outpatient population over 60 years of age. Cephalalgia. 2003;23:953–60.

    Article  Google Scholar 

  11. Lipton RB, Silberstein SD, Stewart WF. An update on the epidemiology of migraine. Headache 1994;(34):319–328.

    Article  CAS  Google Scholar 

  12. Baumel B, Einner LS. Diagnosis and treatment of headache in the elderly. Med Clin North Am. 1991;75:661–75.

    Article  CAS  Google Scholar 

  13. Cook NR, Evans DA, Fundenstein HH, et al. Correlates of headache in a population based cohort of elderly. Arch Neurol. 1989;46:1338–44.

    Article  CAS  Google Scholar 

  14. Cull RE. Investigations of late onset migraine. Scot Med J. 1995;(7):50–2.

    Article  CAS  Google Scholar 

  15. Landy SH, Loho BC. Migraine treatment throughout the life cycle. Expert Rev Neurother. 2005;5(5):343–53.

    Article  CAS  Google Scholar 

  16. Chutka DS, Takahashi PY, Hoel RW. Inappropriate medication for elderly patients. Mayo Clinic Proc. 2004;79:122–39.

    Article  CAS  Google Scholar 

  17. AGS Panel on persistent pain in older person. The management of persistent pain in older person. J Am Geriatrics Society. 2002;(50):205–24.

  18. Burris JE. Pharmacologic approaches to geriatric pain management. Arch Phys Med Rehabilitation. 2004;(85):545–9.

  19. Biondi DM, Saper JR. Geriatric headache. How to make the diagnosis and manage the pain. Geriatric 2000;(55):40–50.

  20. Honkaniemi J, Liimatainen S, Rainesalo S. Haloperidol in the acute treatment of migraine: a randomized ,double –blind ,placebo controlled study. Headache. 2006;46(46):781–7.

    Article  Google Scholar 

  21. Esper C, Factor S. Failure of recognition of drug induced parkinsonism in the elderly. Mov Disord. 2008;23:401–4.

    Article  Google Scholar 

  22. Lipton RB, Preffen D, Newman LC, et al. Headache in the elderly. J Pain Symptom Manag. 1993;8(8):87–9.

    Article  CAS  Google Scholar 

  23. Kimball RW, Friedman AP, Vallejo E. Effect of serotonin in migraine patients. Neurology. 1960;10:107–11.

    Article  CAS  Google Scholar 

  24. Vanmolkot FH, deHoon JW. Acute effects of sumatriptan on aortic blood pressure, stiffen and pressure wave form. Clin Pharmacol Ther. 2006;80(1):85–94.

    Article  CAS  Google Scholar 

  25. Dodick DW, Papademetriou V. Cardiovascular safety of triptans. Cephalalgia. 2000. https://doi.org/10.1111/j.1468-2982.2003.00714.x.

    Article  CAS  Google Scholar 

  26. Wammens-Vander Hajden EA, Rahimtoola H. Risk of ischemic complication related to the intensity of triptan and ergotamine use. Neurology. 2006;67:1128–34.

    Article  Google Scholar 

  27. Banzi R, Cusi C, Randazzo C, et al. SSRIs and SNRIs for prevention of migraine in adults. Cochrane data base of systematic reviews. 2015.

  28. Kirby D, Harrigan S, Ames D. Hyponatremia in elderly psychiatric patients treated with SSRIs and venlafaxine-a retrospective controlled study. Geriatric psychiatry. 2002;17(17):231–7.

    Article  Google Scholar 

  29. Chronicle G, Mu Ueners W. Anticonvulsant drug for migraine prophylaxis. Cochrane Database Syst Rev 2004;(3):1–35.

  30. Arroyos, S., Kramer, G. Treating epilepsy in the elderly. Drug Saf 2001;(26):991–1015.

    Article  CAS  Google Scholar 

  31. Brodie, MJ., Kwan, P. Epilepsy in Elderly People. BMJ 2005;(331):1317–22.

    Article  Google Scholar 

  32. Schwartz JB. Calcium antagonists in the elderly. A risk benefit analysis. Drug Aging. 1996;(9):24–36.

    Article  CAS  Google Scholar 

  33. Opie LH. Calcium channel blockers for hypertension. Dissecting the evidence for adverse events. Am J Hypertens 1997;(10),565–77.

  34. Schrader H, Stovner LJ, Helde G.et al. Prophylactic treatment of migraine with an angiotensin converting enzyme inhibitor (Lisinopril): randomized, placebo controlled, crossover study. BMJ 2001;(332),1–5.

  35. Tronvik E, Stovner LJ, Helde G. Prophylactic treatment of migraine with an angiotensin II receptor blocker. A randomized controlled trial. JAMA, 2003;(289):65–9.

    Article  CAS  Google Scholar 

  36. Silberstein S D. Topiramate in migraine prevention: evidence based medicine from clinical trials. Neurol Sci, 2004;(24):244–245.

  37. Rubio-Beltran E, Labastida-Ramirez A, Viualon C, et al. Is selective 5-HT1F receptor agonism an entity apart from that of the triptan in antimigraine therapy? Pharmacol Therapy. 2018;186:88–97.

    Article  CAS  Google Scholar 

  38. Hoffman J, Goodsby PJ. Emerging targets in migraine. CNS Drugs. 2014;28(28):11–7.

    Article  Google Scholar 

  39. Rubio Beltran E, Kristian H, Labastida A, et al. Lasmiditan and sumatriptan: comparison of in vivo vascular constriction in the dog and in vitro contraction of human arteries. Cephalalgia. 2016;(36):104–5.

  40. Capi M, deAndres F, Lionetto L, et al. Lasmiditan for the treatment of migraine. Expert Opin Investig Drugs. 2017;2(26):227–34.

    Article  Google Scholar 

  41. • Lilly announces positive results for second phase 3 study of Lasmiditan for the acute treatment of migraine (NYSE:LLY).(2018). Available from https://investor.lilly.com/static-files/15cf1efc-da8f-485c-9001-6ff3b432b129. Accessed March 19,2018. These references are important because they include clinical trials of medications for migraine that show possible safety profile in the elderly population.

  42. • CoCo Lucid Pharmaceuticals provides interim update on GLADIATOR (webpage on the internet)Globenewswire Inc.(2016). Available via: https://globenewswire.com/news-release/2016/09/19/872772/0/en/CoLucid-Pharmaceuticals-Provides-Interim-Update-on-GLADIATOR.html. Accessed August 10, 2018. These references are important because they include clinical trials of medications for migraine that show possible safety profile in the elderly population.

  43. Doods H, Hallermayer G, Wu D et al. Pharmacologial profile of BIBN 4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol, 2000;(129):420–423.

    Article  CAS  Google Scholar 

  44. Bigal ME, Walter S. Monoclonal antibodies for migraine preventing calcitonin gene related peptide activity. CNS Drugs. 2014;28:389–99.

    Article  CAS  Google Scholar 

  45. Connor KM, Aurora SK, Loeys T, et al. Long term tolerability of Telcagepant for acute treatment of migraine in a randomized trial. Headache. 2010;51:73–84.

    Article  Google Scholar 

  46. Han TH, Blanchard RL, Palcza J, et al. Single and multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide receptor antagonist in adults. J Clin Pharmacol. 2010;50:1367–76.

    Article  CAS  Google Scholar 

  47. Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 2011;31:712–22.

    Article  Google Scholar 

  48. Ho TW, Mannix LK, Fan X, Fan X, Assaid C, Furtek C, et al. Randomized controlled trial of an horal CGRP antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008;70:1304–12.

    Article  CAS  Google Scholar 

  49. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant) a new oral antagonist of calcitonin gene-related peptide receptor compared with zolmitriptan for acute migraine: a randomized, placebo-controlled, parallel-treatment trial. Lancet. 2008;372:2089–90. https://doi.org/10.1016/S0140-6736(08)61710-9.

    Article  Google Scholar 

  50. Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the acute treatment of migraine. Efficacy, safety, tolerability and functional impact outcomes from a single attack phase 3 study, ACHIEVE 1. Presented at 60th Annual Scientific Meeting of the American Headache Society (AHS 2018); San Francisco, CA; June 28–July 1,2018.

  51. Lipton RB, Coric V, Stock EG, et al. Efficacy, safety and tolerability of rimegepant 75mg ,an oral CGRP receptor antagonist for the acute treatment of migraine: results from a phase 3 ,double blind, randomized, placebo-controlled trial, study 302. Presented at the 60th Annual Scientific Meeting of the American Headache Society (AHS 2018); San Francisco, CA; June 30, 2018.

  52. Efficacy, safety and tolerability of Atogepant for the prevention of chronic migraine. www.clinical trials.gov.

  53. Safety and efficacy of rimegepant for migraine prevention in adults. www.clinical trials.gov.

  54. • Rimegepant and BHV-3500, small molecule CGRP receptor antagonists exhibit no active vasoconstrictive properties in ex vivo human coronary or cerebral artery. (2018). Abstract presentation at annual scientific meeting, San Francisco. These references are important because they include clinical trials of medications for migraine that show possible safety profile in the elderly population.

  55. Dodick DW, Goadsby PJ, Spierings EL, et al. Safety and efficacy of LY2951742 a monoclonal antibody to calcitonin gene related peptide for the prevention of migraine, a phase 2 randomized, double –blind, placebo controlled study. Lancet. 2014;13:885–92.

    Article  CAS  Google Scholar 

  56. Israel H, Neeb L, et al. CGRP monoclonal antibodies for the preventive treatment of migraine. Headache. 2018;22:38.

    Google Scholar 

  57. • Depre C, Analik L, Starling A, et al. A randomized, double blind, placebo controlled study to evaluate the effect of erenumab on exercise time during a treadmill test in patients with stable angina. Cephalalgia. 2017;37:340–1. These references are important because they include clinical trials of medications for migraine that show possible safety profile in the elderly population.

    Google Scholar 

  58. Dodick DW, Turkel CC, Degryse RE, Turkel CC, DeGryse RE, Aurora SK, et al. Onabotulinum toxin a for treatment of chronic migraine: pooled results from the double blind, randomized placebo controlled phases of PREEMPT clinical program. Headache. 2010;50(50):921–36.

    Article  Google Scholar 

  59. Lackovic Z, Boris F, Ivica M, et al. Activity of botulinum toxin type A in cranial dura: implications for treatment of migraine and other headaches. Br J Pharmacol. 2016;173(2):279–91.

    Article  CAS  Google Scholar 

  60. Lauritsen CG, Silberstein SD. Rationale for electrical parameter determination in external trigeminal nerve stimulation (Etns) for migraine. 2018. doi https://doi.org/10.1177/0333102418796781

    Article  Google Scholar 

  61. Schoenen J, Vandersmissen B, Jeangette S, Herroelen L, Vandenheede M, Gerard P, et al. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology. 2013;80:697–704.

    Article  Google Scholar 

  62. Magis D, Salva S, d’Elia TS, et al. Safety and patients’ satisfaction of transcutaneous supra orbital neuro stimulation (tSNS) with Cefaly device in headache treatment: a survey of 2,313 headache sufferers in the general population. J Headache Pain. 2013;14:95.

    Article  Google Scholar 

  63. Chou DE, Shnavderman Y, Winegarner D, et al. Acute migraine therapy with external trigeminal neuro stimulation (ACME): a randomized controlled trial. 2018. doi https://doi.org/10.1177/0333102418811573.

    Article  Google Scholar 

  64. Irwin SL, Qubty W, Allen IT, Allen IE, Patniyot I, Goadsby PJ, et al. Transcranial magnetic stimulation for migraine prevention in adolescents: a pilot open label study. Headache. 2018;58:724–31.

    Article  Google Scholar 

  65. Lipton RB, Dodick DW, Silberstein SD, Silberstein SD, Saper JR, Aurora SK, et al. Single pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomized, double blind ,parallel group, sham controlled trial. Lancet Neurol. 2010;9:373–80.

    Article  Google Scholar 

  66. Martelli P, Barbanti P, Grazzi L, et al. Noninvasive vagus nerve stimulation for consistent effects of non-invasive vagus nerve stimulation (n VNS) for the acute treatment of migraine. J Headache. 2018. https://doi.org/10.1186/s10194-018-0929-0.

  67. Goadsby PJ, Grosberg BM, Mausko A, et al. Effect of noninvasive vagus nerve stimulation on acute migraine: an open label pilot study. Cephalalgia. 2014;34:986–93.

    Article  CAS  Google Scholar 

  68. • Taosrelli C, Grazzi L, Tommaso M, et al. Noninvasive vagus nerve stimulation as acute therapy for migraine, the randomized PRESTO study. Neurology. 2018;91:364–73. These references are important because they include clinical trials of medications for migraine that show possible safety profile in the elderly population.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Med star Georgetown University Hospital, 3800 Reservoir Road NW, 7 PHC, Washington, DC, 20007, USA

    Shema Mathew & Jessica Ailani

Authors
  1. Shema Mathew
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jessica Ailani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shema Mathew.

Ethics declarations

Conflict of Interest

Shema Mathew and Jessica Ailani declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Episodic Migraine

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mathew, S., Ailani, J. Traditional and Novel Migraine Therapy in the Aging Population. Curr Pain Headache Rep 23, 42 (2019). https://doi.org/10.1007/s11916-019-0789-6

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11916-019-0789-6

Keywords

Search

Navigation